NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 203 filers reported holding NEVRO CORP in Q2 2017. The put-call ratio across all filers is 1.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $6,296,000 | +44.4% | 67,200 | +12.0% | 3.08% | +18.7% |
| Q4 2016 | $4,360,000 | -45.8% | 60,000 | -22.1% | 2.60% | -20.9% |
| Q3 2016 | $8,038,000 | +29.0% | 77,000 | -8.9% | 3.28% | +23.0% |
| Q2 2016 | $6,232,000 | +76.8% | 84,500 | +34.9% | 2.67% | +25.3% |
| Q1 2016 | $3,525,000 | -14.4% | 62,656 | +2.7% | 2.13% | +0.5% |
| Q4 2015 | $4,118,000 | – | 61,000 | – | 2.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |